Hansen touts 1st clinical use of robotic Magellan microcath driver

Hansen Medical (NSDQ:HNSN) said today its Magellan microcatheter driver has been used in its 1st clinical procedure, performing an embolization in the peripheral vasculature to treat a benign prostatic hyperplasia.

The procedure was performed in Paris at the Hôpital Européen Georges Pompidou by device clinical study principal investigator Dr. Marc Sapoval and Dr. Gregory Amouyal, the Mountain View, Calif.-based company said.

“We are pleased to complete the world’s 1st clinical procedure using the Magellan Microcatheter Driver as part of this clinical study. Manual control of microcatheters and microwires can be challenging, particularly in tortuous anatomy. By utilizing the Microcatheter Driver in conjunction with the Magellan 6Fr Robotic Catheter, we are enhancing the utility of the Magellan Robotic System and realizing its potential in a pivotal aspect of embolization procedures,” Sapoval said in a press release.

The Magellan system drives Magellan robotic catheters and guide wires in minimally-invasive endovascular procedures and can be controlled remotely to allow for the use of interventional fluoroscopy during the procedures without risking radiation exposure, the company said.

“Today’s announcement is an important milestone for Hansen Medical. Upon regulatory approval, the Magellan Robotic Microcatheter Driver will be an important expansion of our product line and represents a step forward in our goal toward vascular interventions that will eventually be performed 100% robotically. By advancing microcatheters with the Magellan System, we expect to add greater precision while continuing to provide physicians the benefit of reduced exposure to procedural radiation. We are pleased to partner with HEGP-APHP as part of our shared commitment to improve the care of patients through the application of advanced technologies,” CEO Cary Vance said in prepared remarks.

In October, Hansen Medical said it inked an agreement with AB Medica Sagl to operate as the exclusive distributor of its Magellan robotic system in Switzerland.

AB Medica Sagl also serves as the company’s exclusive distributor in Italy, Hansen Medical said. Hansen Medical shipped one of its Magellan robotic systems to AB Medica as part of the agreement.

In September, Hansen Medical pulled the trigger on a reverse 10-for-1 stock split in which HNSN shareholders received 1 share for every 10 they owned.

The reverse split went into effect Sept. 22, according to a regulatory filing, sending HNSN shares down -13% to $4.35 apiece.

The post Hansen touts 1st clinical use of robotic Magellan microcath driver appeared first on MassDevice.

from MassDevice http://ift.tt/1XQo1qk